Drug profile erlonat is a Natco pharma item which is containing a functioning substance known as Erlotinib, a first line medication of decision in metastatic phase of non little cell lung tumor. erlonat 150mg is normally endorsed for the patients who are not counters to less than one chemotherapy regimen. erlonat 150mg tablet is synthetically described as quinazoline subordinate, with hostile to neoplastic impact against tumor cells. erlonat is pharmacologically arranged as tyrosine kinase inhibitor. erlonat 150mg is altogether raising the serum aminotransferase levels amid the treatment and this may causes liver wounds. erlonat 150mg tablet tablets are containing 150mg of Erlotinib as a hostile to tumor specialist. PRODUCT DETAILS Brand name: Erlonat Active constituent: Erlotinib Strength: 150MG Mfg: Natco pharma Pack: 30 tablets per container Catego...